Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia
Revaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) has remained controversial due to lack of immunological data and fear of side effects. We re-vaccinated 61 elderly patients (median age 75 years), who had a history of hospital treatment for pneumonia, with PPV on average 5.3...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2003-12, Vol.22 (1), p.96-103 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 103 |
|---|---|
| container_issue | 1 |
| container_start_page | 96 |
| container_title | Vaccine |
| container_volume | 22 |
| creator | Törling, Jan Hedlund, Jonas Konradsen, Helle Bossen Örtqvist, Åke |
| description | Revaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) has remained controversial due to lack of immunological data and fear of side effects. We re-vaccinated 61 elderly patients (median age 75 years), who had a history of hospital treatment for pneumonia, with PPV on average 5.3 years after their primary vaccination. Revaccination resulted in significant increases of the geometric mean antibody concentration (GMC) and the geometric mean antibody fold increase (GMFI), although to lower levels than after primary vaccination. 36/61 (59%) of the patients responded with a GMFI of ≥2 to ≥2 of six serotypes. Local reactions to revaccination were common (63%), but mild, and there were no serious adverse events. We conclude that revaccination of elderly with PPV after 5–10 years is safe and induce a significant immune response in a majority of persons. |
| doi_str_mv | 10.1016/S0264-410X(03)00521-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_587820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03005218</els_id><sourcerecordid>19163369</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-f99c800284ec9b1be2a2c1a93121a5a5b9c18149ea488b9cf777b72bcde4e1dc3</originalsourceid><addsrcrecordid>eNqF0luL1TAQAOAgintc_QlKQBR9qObapk8iizdYELyAbyFNpp6sPUk3ac9y_oE_25xt2QVf9ikXvhlmmEHoKSVvKKH12--E1aISlPx6RfhrQiSjlbqHNlQ1vGKSqvtoc0NO0KOcL0hRnLYP0QkVNRGyqTfo7zfYG2t9MJOPAV_5aYunLWDGq70ZIEx4DDDvoo3WmgGPcTjk4rcmeQd4CQXsA9555waozG9w2ASHYXCQhgMeIeUYMh4T7H2cc_maEpipsD6mNXvw5jF60Jshw5P1PEU_P374cfa5Ov_66cvZ-_PKCqWmqm9bqwhhSoBtO9oBM8xS03LKqJFGdq2liooWTOHl0TdN0zWssw4EUGf5KaqWvPkKxrnTY_I7kw46Gq_Xrz_lBlqqRjFS_MvFjylezpAnvfPZwjCYAKUd3VAuec3EnZC2tOa8bgt8_h-8iHMKpWlNpagV4YKwouSibIo5J-hvKqVEHzdAX2-APo5XE66vN0CrEvdszT53O3C3UevIC3ixApPLSPtkgvX51knBWCOP_bxbHJRp7D0kna2HYMH5BHbSLvo7SvkHDtnQLw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1546803402</pqid></control><display><type>article</type><title>Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Törling, Jan ; Hedlund, Jonas ; Konradsen, Helle Bossen ; Örtqvist, Åke</creator><creatorcontrib>Törling, Jan ; Hedlund, Jonas ; Konradsen, Helle Bossen ; Örtqvist, Åke</creatorcontrib><description>Revaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) has remained controversial due to lack of immunological data and fear of side effects. We re-vaccinated 61 elderly patients (median age 75 years), who had a history of hospital treatment for pneumonia, with PPV on average 5.3 years after their primary vaccination. Revaccination resulted in significant increases of the geometric mean antibody concentration (GMC) and the geometric mean antibody fold increase (GMFI), although to lower levels than after primary vaccination. 36/61 (59%) of the patients responded with a GMFI of ≥2 to ≥2 of six serotypes. Local reactions to revaccination were common (63%), but mild, and there were no serious adverse events. We conclude that revaccination of elderly with PPV after 5–10 years is safe and induce a significant immune response in a majority of persons.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(03)00521-8</identifier><identifier>PMID: 14604576</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Age ; Aged ; Antibodies, Bacterial - analysis ; Antibodies, Bacterial - biosynthesis ; Applied microbiology ; Bacteriology ; Biological and medical sciences ; Chronic illnesses ; Cohort Studies ; Disease ; Female ; Fundamental and applied biological sciences. Psychology ; Heart failure ; Hospitalization ; Humans ; Immune response ; Injections, Intramuscular ; Lipopolysaccharides - administration & dosage ; Lipopolysaccharides - adverse effects ; Lipopolysaccharides - immunology ; Male ; Microbiology ; Middle age ; Middle Aged ; Miscellaneous ; Mortality ; Older people ; Pneumococcal vaccine ; Pneumococcal Vaccines - administration & dosage ; Pneumococcal Vaccines - adverse effects ; Pneumococcal Vaccines - immunology ; Pneumonia ; Pneumonia, Pneumococcal - immunology ; Pneumonia, Pneumococcal - therapy ; polysaccharides ; Polysaccharides - immunology ; Revaccination ; Streptococcus infections ; Streptococcus pneumoniae ; Studies ; Time Factors ; Vaccination ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Variance analysis</subject><ispartof>Vaccine, 2003-12, Vol.22 (1), p.96-103</ispartof><rights>2003 Elsevier Ltd</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Dec 8, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-f99c800284ec9b1be2a2c1a93121a5a5b9c18149ea488b9cf777b72bcde4e1dc3</citedby><cites>FETCH-LOGICAL-c488t-f99c800284ec9b1be2a2c1a93121a5a5b9c18149ea488b9cf777b72bcde4e1dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X03005218$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15422754$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14604576$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1947956$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Törling, Jan</creatorcontrib><creatorcontrib>Hedlund, Jonas</creatorcontrib><creatorcontrib>Konradsen, Helle Bossen</creatorcontrib><creatorcontrib>Örtqvist, Åke</creatorcontrib><title>Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Revaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) has remained controversial due to lack of immunological data and fear of side effects. We re-vaccinated 61 elderly patients (median age 75 years), who had a history of hospital treatment for pneumonia, with PPV on average 5.3 years after their primary vaccination. Revaccination resulted in significant increases of the geometric mean antibody concentration (GMC) and the geometric mean antibody fold increase (GMFI), although to lower levels than after primary vaccination. 36/61 (59%) of the patients responded with a GMFI of ≥2 to ≥2 of six serotypes. Local reactions to revaccination were common (63%), but mild, and there were no serious adverse events. We conclude that revaccination of elderly with PPV after 5–10 years is safe and induce a significant immune response in a majority of persons.</description><subject>Age</subject><subject>Aged</subject><subject>Antibodies, Bacterial - analysis</subject><subject>Antibodies, Bacterial - biosynthesis</subject><subject>Applied microbiology</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Chronic illnesses</subject><subject>Cohort Studies</subject><subject>Disease</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart failure</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Immune response</subject><subject>Injections, Intramuscular</subject><subject>Lipopolysaccharides - administration & dosage</subject><subject>Lipopolysaccharides - adverse effects</subject><subject>Lipopolysaccharides - immunology</subject><subject>Male</subject><subject>Microbiology</subject><subject>Middle age</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Mortality</subject><subject>Older people</subject><subject>Pneumococcal vaccine</subject><subject>Pneumococcal Vaccines - administration & dosage</subject><subject>Pneumococcal Vaccines - adverse effects</subject><subject>Pneumococcal Vaccines - immunology</subject><subject>Pneumonia</subject><subject>Pneumonia, Pneumococcal - immunology</subject><subject>Pneumonia, Pneumococcal - therapy</subject><subject>polysaccharides</subject><subject>Polysaccharides - immunology</subject><subject>Revaccination</subject><subject>Streptococcus infections</subject><subject>Streptococcus pneumoniae</subject><subject>Studies</subject><subject>Time Factors</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Variance analysis</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0luL1TAQAOAgintc_QlKQBR9qObapk8iizdYELyAbyFNpp6sPUk3ac9y_oE_25xt2QVf9ikXvhlmmEHoKSVvKKH12--E1aISlPx6RfhrQiSjlbqHNlQ1vGKSqvtoc0NO0KOcL0hRnLYP0QkVNRGyqTfo7zfYG2t9MJOPAV_5aYunLWDGq70ZIEx4DDDvoo3WmgGPcTjk4rcmeQd4CQXsA9555waozG9w2ASHYXCQhgMeIeUYMh4T7H2cc_maEpipsD6mNXvw5jF60Jshw5P1PEU_P374cfa5Ov_66cvZ-_PKCqWmqm9bqwhhSoBtO9oBM8xS03LKqJFGdq2liooWTOHl0TdN0zWssw4EUGf5KaqWvPkKxrnTY_I7kw46Gq_Xrz_lBlqqRjFS_MvFjylezpAnvfPZwjCYAKUd3VAuec3EnZC2tOa8bgt8_h-8iHMKpWlNpagV4YKwouSibIo5J-hvKqVEHzdAX2-APo5XE66vN0CrEvdszT53O3C3UevIC3ixApPLSPtkgvX51knBWCOP_bxbHJRp7D0kna2HYMH5BHbSLvo7SvkHDtnQLw</recordid><startdate>20031208</startdate><enddate>20031208</enddate><creator>Törling, Jan</creator><creator>Hedlund, Jonas</creator><creator>Konradsen, Helle Bossen</creator><creator>Örtqvist, Åke</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20031208</creationdate><title>Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia</title><author>Törling, Jan ; Hedlund, Jonas ; Konradsen, Helle Bossen ; Örtqvist, Åke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-f99c800284ec9b1be2a2c1a93121a5a5b9c18149ea488b9cf777b72bcde4e1dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Age</topic><topic>Aged</topic><topic>Antibodies, Bacterial - analysis</topic><topic>Antibodies, Bacterial - biosynthesis</topic><topic>Applied microbiology</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Chronic illnesses</topic><topic>Cohort Studies</topic><topic>Disease</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart failure</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Immune response</topic><topic>Injections, Intramuscular</topic><topic>Lipopolysaccharides - administration & dosage</topic><topic>Lipopolysaccharides - adverse effects</topic><topic>Lipopolysaccharides - immunology</topic><topic>Male</topic><topic>Microbiology</topic><topic>Middle age</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Mortality</topic><topic>Older people</topic><topic>Pneumococcal vaccine</topic><topic>Pneumococcal Vaccines - administration & dosage</topic><topic>Pneumococcal Vaccines - adverse effects</topic><topic>Pneumococcal Vaccines - immunology</topic><topic>Pneumonia</topic><topic>Pneumonia, Pneumococcal - immunology</topic><topic>Pneumonia, Pneumococcal - therapy</topic><topic>polysaccharides</topic><topic>Polysaccharides - immunology</topic><topic>Revaccination</topic><topic>Streptococcus infections</topic><topic>Streptococcus pneumoniae</topic><topic>Studies</topic><topic>Time Factors</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Törling, Jan</creatorcontrib><creatorcontrib>Hedlund, Jonas</creatorcontrib><creatorcontrib>Konradsen, Helle Bossen</creatorcontrib><creatorcontrib>Örtqvist, Åke</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Törling, Jan</au><au>Hedlund, Jonas</au><au>Konradsen, Helle Bossen</au><au>Örtqvist, Åke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2003-12-08</date><risdate>2003</risdate><volume>22</volume><issue>1</issue><spage>96</spage><epage>103</epage><pages>96-103</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Revaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) has remained controversial due to lack of immunological data and fear of side effects. We re-vaccinated 61 elderly patients (median age 75 years), who had a history of hospital treatment for pneumonia, with PPV on average 5.3 years after their primary vaccination. Revaccination resulted in significant increases of the geometric mean antibody concentration (GMC) and the geometric mean antibody fold increase (GMFI), although to lower levels than after primary vaccination. 36/61 (59%) of the patients responded with a GMFI of ≥2 to ≥2 of six serotypes. Local reactions to revaccination were common (63%), but mild, and there were no serious adverse events. We conclude that revaccination of elderly with PPV after 5–10 years is safe and induce a significant immune response in a majority of persons.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>14604576</pmid><doi>10.1016/S0264-410X(03)00521-8</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2003-12, Vol.22 (1), p.96-103 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_587820 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Age Aged Antibodies, Bacterial - analysis Antibodies, Bacterial - biosynthesis Applied microbiology Bacteriology Biological and medical sciences Chronic illnesses Cohort Studies Disease Female Fundamental and applied biological sciences. Psychology Heart failure Hospitalization Humans Immune response Injections, Intramuscular Lipopolysaccharides - administration & dosage Lipopolysaccharides - adverse effects Lipopolysaccharides - immunology Male Microbiology Middle age Middle Aged Miscellaneous Mortality Older people Pneumococcal vaccine Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - adverse effects Pneumococcal Vaccines - immunology Pneumonia Pneumonia, Pneumococcal - immunology Pneumonia, Pneumococcal - therapy polysaccharides Polysaccharides - immunology Revaccination Streptococcus infections Streptococcus pneumoniae Studies Time Factors Vaccination Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Variance analysis |
| title | Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T09%3A19%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Revaccination%20with%20the%2023-valent%20pneumococcal%20polysaccharide%20vaccine%20in%20middle-aged%20and%20elderly%20persons%20previously%20treated%20for%20pneumonia&rft.jtitle=Vaccine&rft.au=T%C3%B6rling,%20Jan&rft.date=2003-12-08&rft.volume=22&rft.issue=1&rft.spage=96&rft.epage=103&rft.pages=96-103&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(03)00521-8&rft_dat=%3Cproquest_swepu%3E19163369%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1546803402&rft_id=info:pmid/14604576&rft_els_id=S0264410X03005218&rfr_iscdi=true |